Targets › FAAH
2 programs from 2 companies in 4 trials: 3 Phase 2, 1 Phase 1; Neurology, Other; next expected readout Dec 2026.
Catalyzes the hydrolysis of endogenous amidated lipids like the sleep-inducing lipid oleamide ((9Z)-octadecenamide), the endocannabinoid anandamide (N-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-ethanolamine), as well as other fatty amides, to their corresponding fatty acids, thereby regulating the signaling functions of these molecules. Hydrolyzes polyunsaturated substrate anandamide preferentially as compared to…. (UniProt, O00519)
Open in Phaseline: the race on FAAH, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | Irafamdastat (BMS-986368, CC-97489) FAAH/MAGL inhibitor | FAAH, MAGL | Phase 2 | Multiple Sclerosis Spasticity; Agitation; Healthy Volunteers | Dec 2026 |
| Alberto Esquenazi | BMS-986368 FAAH/MAGL inhibitor | FAAH, MAGL | Phase 2 | Post-Stroke Spasticity | Jun 2027 |
Post-Stroke Spasticity (1) Multiple Sclerosis Spasticity (1) Agitation (1) Healthy Volunteers (1)
small molecule (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.